

## CREATINE KINASE MB (CK-MB)

REF: 239 000 (5 x 5 ml) 50 Test  
REF: 239 001 (6 x 5 ml) 60 Test  
REF: 239 002 (6 x 10 ml) 120 Test  
REF: 239 003 (5 x 25 ml) 250 Test  
REF: 239 004 (6 x 20 ml) 240 Test

### Intended Use

Spectrum Diagnostics Creatine Kinase MB (CK-MB) reagent is intended for the in-vitro quantitative, diagnostic determination of Creatine kinase MB in human serum on both automated and manual systems.

### Background

Creatine kinase (CK) is an enzyme which is contained in heart, brain and skeletal muscles. Thus, an increase of circulating level of CK may be associated to myocardial infarction, acute cerebrovascular disease, trauma or diseases of skeletal muscles. After a myocardial infarct, CK level begins raising between 4th and 6th hour after first acute symptoms, reaching the peak between 18th and 30th hour and coming back to normal values during the 3rd day. CK is present in three different isoenzymatic forms, which could be separated by electrophoresis or column chromatography; each form is originated in different body tissues, paying off their diagnostic determinations. CK exists in serum in dimeric forms as CK-MM, CK-MB and CK-BB and as macro-enzymes. Measurement of CK-MB is a quite specific test for detection of cardiac muscle damage and is therefore used for diagnosis and monitoring of myocardial infarction.

### Method

After immunoinhibition with antibodies to the CK-M subunit, the CK-B activity is determined with a method according to the recommendations of the International Federation of Clinical Chemistry (IFCC).

### Assay Principle

A specific antibody inhibits the M subunits of CK-MM and CK-MB, and thus allows determination of the B subunit of CK-MB (assuming the absence of CK-BB or CK-1). CK-B catalytic concentration, which corresponds to half of CK-MB concentration, is determined from the rate of NADPH formation, measured at 340 nm, by means of the hexokinase (HK) and glucose-6-phosphate dehydrogenase (G6PDH) coupled reactions<sup>1,3</sup>.



### Reagents

#### Reagent 1 (pH 6.7) (Buffer / Coenzyme)

Imidazol	125 mmol/L
D-Glucose	25 mmol/L
N-Acetyl-L-Cysteine	25 mmol/L
Magnesium acetate	12.5 mmol/L
NADP	2.5 mmol/L
EDTA	2 mmol/L

#### Reagent 2 (Enzymes)

ADP	15.2 mmol/L
AMP	25 mmol/L
P1,P5-di (adenosine-5'-) penta-phosphate	103 mmol/L
Glucose-6-phosphate Dehydrogenase (G6PDH)	9 KU/L
Creatine phosphate	250 mmol/L
Hexokinase (HK)	3 KU/L
Anti-human-CK-M.	

### Precautions and Warnings

Do not ingest or inhale. In case of contact with eyes or skin; rinse immediately with plenty of soap and water. In case of severe injuries; seek medical advice immediately.

### SYMBOLS IN PRODUCT LABELLING

	Authorised Representative		Use by/Expiration Date
	For in-vitro diagnostic use		CAUTION. Consult instructions for use
	Batch Code/Lot number		Manufactured by
	Catalogue Number		(Xi) - Irritant
	Consult instructions for use		
	Temperature Limitation		

### Storage and Stability

All the components of the kit are stable until the expiration date on the label when stored tightly closed at 2-8°C, protected from light and contaminations prevented during their use.

### Deterioration

Do not use spectrum CKMB reagent in case of presence of particles or turbidity.

### Reagent preparation, Storage, and Stability

CK-MB reagents are supplied ready-to-use and stable up to the expiry date labeled on the bottles when properly stored refrigerated at 2 – 8 °C. Once opened, the opened vial is stable for 1 month at the specified temperature.

### Specimen Collection and Preservation

Serum free of hemolysis is the preferred specimen. Plasma containing heparin, EDTA, citrate or fluoride may produce unpredictable reaction rates. Stable for 2 hours at 20-25 °C, 5 days at 4-8 °C. Total CK concentration in the sample must be lower than 1000 U/L. Dilute the serum 1/2 if necessary, with NaCl (150 mmol/L).

### System Parameters

Wavelength	340 nm (334-365 nm)
Optical path	1 cm
Assay type	Fixed rate
Direction	Increase
Sample: Reagent Ratio	1:25
Temperature	37 °C
Zero adjustment	against air
Sensitivity	2 U/L
Linearity	2000 U/L

### Procedure

Pipette into a cuvette:

**Reagent (R1)** 400 µl

**Reagent (R2)** 100 µl

**Specimen** 20 µl

Incubate for 5 minutes at 37 °C then read (A1). After 5 minutes, read (A2).

### Calculation

$$(A2-A1) \times 1651 = \text{U/L CKMB}$$

Units: One international unit (IU) is the amount of enzyme that transforms 1 µmol of substrate per minute, in standard conditions. The concentration is expressed in units per liter of sample (U/L).

### Expected values

The discrimination value for myocardial infarction is around 25 U/L. However, an index higher than 6% of total CK concentration discriminates better. These values are for orientation purpose; each laboratory should establish its own reference range.

### Quality Control

Normal and abnormal commercial control serum of known concentrations should be analyzed with each run.

## Performance Characteristics

### Precision

Within run (Repeatability)

	Level 1	Level 2
n	20	20
Mean (U/L)	45	129
SD	3.01	19.7
CV%	3.5	3.2

Run to run (Reproducibility)

	Level 1	Level 2
n	20	20
Mean (U/L)	40	130
SD	2.15	15.0
CV%	2.8	2.3

### Methods Comparison

A comparison between Spectrum Diagnostics CK-MB reagent and a commercial reagent of the same methodology was performed on 20 human sera. A correlation of 0.979 was obtained.

### Sensitivity

When run as recommended, the minimum detection limit of the assay is 2.0 U/L.

### Linearity

The reaction is linear up to CK-MB concentration of 2000 U/l; specimens showing higher concentration should be diluted 1+2 using physiological saline and repeat the assay (result×3).

### Interferences

Haemoglobin (< 2.5 g/L), lipemia (Lipids < 900 mg/dL) and Bilirubin (< 25 mg/dL) do not interfere. Presences in the sample of above normal concentrations of CK-BB or adenilate kinase, and of macro or mitochondrial CK interfere. Other drugs and substances may interfere.

### References

1. IFCC methods for the measurement of catalytic concentration of enzymes. Part 7: IFCC method for creatine kinase. JIFCC 1989; 1: 130-139.
2. Tietz Textbook of Clinical Chemistry, 3rd edition. Burtis CA, Ashwood ER. WB Saunders Co., 1999.
3. Friedman and Young. Effects of disease on clinical laboratory tests, 3th ed. AACC Press, 1997.
4. Urdal P and Landaas S. Clin Chem 1979; 25: 461-465.
5. Young DS. Effects of drugs on clinical laboratory tests, 3th ed. AACC Press, 1997.

ORDERING INFORMATION	
CATALOG NO.	QUANTITY
239 000	5 x 5 ml
239 001	6 x 5 ml
239 002	6 x 10 ml
239 003	5 x 25 ml
239 004	6 x 20 ml



**Egyptian Company for Biotechnology (S.A.E)**

Obour city industrial area. block 20008 piece 19 A. Cairo. Egypt.

Tel: +202 4489 2248 - Fax: +202 4489 2247

www.spectrum-diagnostics.com

E-mail: info@spectrum-diagnostics.com



**MDSS GmbH**  
Schiffgraben 41  
30175 Hannover, Germany



IFUFCC12

Rev.(13), 15/6/2022